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 Session I: The Brain and Immune System Interplay in 
Acute Stroke 
 Ángel Chamorro Reviewed Recent Studies on the 
Benefits and Harms of the Innate and Adaptive 
Immune Response after Acute Stroke
 Ángel Chamorro reviewed the recent clinical and ex-
perimental studies on the benefits and harms of the in-
nate and adaptive immune response after acute stroke [1]. 
The Toll-like receptors and the lectin pathway of comple-
ment activation were identified as innate amplifiers of the 
inflammatory cascade after stroke. The dynamics of dif-
ferent populations of lymphocytes in stroke were de-
scribed, including the effects of T cells and B cells on dif-
ferent neural cells, the controversial effects of regulatory 
T cells, and the role of regulatory B cells. Recently report-
ed mechanisms of infection after acute stroke include a 
noradrenaline-mediated activation of hepatic invariant 
natural killer T cells and release of acetycholine in the 
spleen by T memory cells. Additional recent studies in 
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 Abstract 
 The European Stroke Organisation held its first European 
Stroke Science Workshop in Garmisch-Partenkirchen, Ger-
many (December 15–17, 2011). Stroke experts based in Eu-
rope were invited to present and discuss their current re-
search. The scope of the workshop was to review the most 
recent findings of selected topics in stroke, to exchange 
ideas, to stimulate new research, and to enhance collabora-
tion between European stroke research groups. Seven scien-
tific sessions were held, each starting with a keynote lecture 
to review the state of the art of the given topic, followed by 
4 or 5 short presentations by experts. They were asked to 
limit their presentations to 10 slides containing only recent 
information. The meeting was organized by the executive 
committee of the European Stroke Organisation (Heinrich 
Mattle, chairman, Michael Brainin, Angel Chamorro, Werner 
Hacke, Didier Leys) and supported by the European Stroke 
Conference (Michael Hennerici). The following sections sum-
marize the content of the workshop. 
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stroke patients show an increased presence of neuronal 
and myelin antigens in lymph nodes of the lymphatic 
drainage of the central nervous system [2]. The cellular 
source of the neural antigens disclose antigen-specific au-
toimmune responses, either protective (neurons) or del-
eterious (myelin). Collectively, these data emphasize the 
double-edged nature of the crosstalk between the brain 
and the immune system, and the strong need for further 
translational research to unravel the role of different T-
cell populations to damaging and reparative processes 
that follow acute stroke.
 Roland Veltkamp, Heidelberg, Germany, Discussed 
Roles of Immunodepression vs. Immunomodulation 
after Ischemic Stroke
 Roland Veltkamp (Heidelberg, Germany) discussed 
the roles of immunodepression vs immunomodulation 
after ischemic stroke, including a decrease of the number 
and activity of immune cells, which results in an in-
creased risk of infections. Hallmarks of this response are 
decreased function of monocytes and lymphocytopenia. 
Suppression of the antibacterial surveillance function of 
immune cells after stroke in humans and rodents results 
primarily from extensive brain infarction, whereas the 
immune system alterations are more subtle after smaller 
infarctions. There is a shift toward more regulatory T 
cells, which modulates the activity of microglia and the 
activation of invading CD4+ T cells. Inhibition of the leu-
kocyte adhesion molecule 4-integrin or its endothelial 
counterpart vascular cell adhesion molecule to reduce 
brain injury in moderate ischemia was also discussed [3] 
Current evidence also suggests a major role for the sym-
pathetic system, the hypothalamic-pituitary-adrenal 
axis, and the vagal nerve in facilitating the crosstalk be-
tween the injured brain and the immune system, al-
though the signals underlying their activation and dys-
function remain to be better-elucidated.
 Andreas Meisel, Berlin, Germany, Addressed the 
Immune System in Subarachnoid Hemorrhage
 Comparable to acute central nervous system injury 
and ischemic stroke [4], patients with subarachnoid hem-
orrhage have development of a temporary but rapid im-
munodepression [5]. Twenty percent of these patients have 
development of pneumonia. Within 24 h of subarachnoid 
hemorrhage, patients have development of lymphopenia 
of CD4+ T cells, CD8+ T cells, and NK cells, and a dimin-
ished release of proinflammatory cytokines involved in 
antibacterial defense, such as lymphocytic interferon- 
and monocytic tumor necrosis factor-. Magnitude and 
duration of the immunodepression correlate with the se-
verity of subarachnoid hemorrhage. Whereas in asymp-
tomatic patients immunity is recovered within 3 to 5 days, 
symptomatic patients with delayed cerebral ischemia have 
development in persistent immune suppression. Persis-
tent immunodepression is strongly correlated with sub-
arachnoid hemorrhage-associated pneumonia. Markers 
such as monocyte human leukocyte antigen-DR expres-
sion might help target those at greatest risk.
 Xabier Urra, Barcelona, Spain, Summarized the Role 
of Monocytes in Acute Stroke
 The number of monocytes reaching the human brain 
increases after stroke but little is known about their func-
tion. Flow cytometry in stroke patients shows a reduced 
expression of antigen-presenting molecules and greater 
expression of Toll-like receptor-4. After ex vivo stimula-
tion with lipopolysaccharide, monocytes show a reduced 
capacity to produce tumor necrosis factor-, whereas the 
production of interleukin-10 is maintained [6]. Poor prog-
nosis after stroke is associated with higher expression in 
monocytes of Toll-like receptor-4 and predominance of 
classic inflammatory monocytes over minor populations 
of reparative CD16+ monocytes. Infections are associated 
with a low expression of antigen-presenting molecules, 
costimulatory signals, and adhesion molecules, and a low-
er production of tumor necrosis factor-.
 The Prevention of Infection in Acute Stroke Was 
Addressed by Diederik van de Beek, Amsterdam, 
The Netherlands 
 Several studies have evaluated the preventive use of 
antibiotics in patients with acute stroke with conflicting 
results. In a systematic overview and meta-analysis of 
randomized clinical trials, preventive antibiotics reduced 
the risk of infection but did not reduce mortality [7]. In 
the NeuMast (NCT00930020), 330 patients with isch-
emic stroke will be randomized between minocycline or 
placebo; 165 patients have been included and an inter-
im analysis is being performed. The second trial
(ISRCTN37118456) is a pragmatic cluster randomized 
trial with a blinded endpoint (chest infections). Patients 
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(n = 800) with stroke plus swallowing disorder have been 
included and preventive use of amoxicillin and clarithro-
mycin is compared with standard care. Finally, the Pre-
ventive Antibiotics in Stroke Study (ISRCTN66140176), a 
multicenter, prospective, randomized, open-label, blind-
ed endpoint trial, investigates whether the preventive use 
of ceftriaxone improves functional outcome in patients 
with stroke. As of now, ;800 of the aimed 3,200 patients 
have been included.
 Session II: Hypothermia and Neuroprotection 
 Ulrich Dirnagl from Berlin Addressed the Question, 
Why Did All Clinical Neuroprotectant Trials Fail?
 The translation from bench results is frequently irratio-
nal and limited preclinical data are used to rush into clin-
ical development [8]. Inadequate models often are used 
and trial design suffers from bias, low power, small sample 
sizes, lack of randomization and blinding, inadequate 
time windows, and incorrect dosages. A major issue re-
mains the difference between uniform strokes in experi-
mental juvenile animals vs heterogeneity in human stroke. 
He also highlighted the complexity of pathophysiology of 
brain ischemia and expanded on the fact that targeting a 
highly elective single mechanism like 1 transcription fac-
tor or a single channel will not succeed in clinical trials. 
Agents should be pleiotropic. His conclusion was that neu-
roprotection is not dead and translation may work if pre-
clinical research quality is improved and clinical develop-
ment is robust and takes care of time effects, selection of 
patients, and surrogate endpoints in early development.
 Bart van der Worp, Utrecht, Holland, Opened the 
Discussion of Hypothermia in Acute Ischemic Stroke
 Bart van der Worp from Utrecht, Holland, opened the 
discussion of hypothermia in acute ischemic stroke by 
introducing the basic design of a large randomized clini-
cal trial, EuroHYP-1, to be funded by the European Union 
as part of the FP7 Program. It will include awake patients 
with acute ischemic stroke who will be cooled to a target 
temperature of 34–35 ° C within 6 h after symptom onset. 
Cooling will be maintained for 24 h and outcome will be 
tested at 3 years using the modified Rankin scale. Cool-
ing will be initiated with an intravenous infusion of 20 
ml/kg cooled normal saline over 30–60 min (temperature 
4 ° C), followed by either surface cooling or endovascular 
cooling for 24 h. Because it is impossible to perform this 
in a double-blind session, assessors will be blinded to 
treatment allocation at 3 months (probe design). The tri-
al will have 750 patients per arm and is designed to show 
a 7% absolute improvement and a 5% significance level.
 Derk Krieger, Copenhagen, Denmark, Summarized 
the Experience of Therapeutic Hypothermia in 
Spontaneous Intracerebral Hemorrhage
 Derk Krieger out that few experimental models had 
approached this problem. Although there has been some 
effect on hemorrhage-associated edema, clinical benefit 
has been rarely reported. A recent clinical pilot study 
from Erlangen on therapeutic hypothermia in patients 
with large symptomatic intracerebral hemorrhage com-
pared with historic matched controls did not show any 
major differences in outcome. In summary, the experi-
mental and clinical evidence for hypothermia in acute 
ischemic stroke is scarce and does not yet suggest the de-
sign of a large randomized clinical trial.
 Jesper Petersson, Lund, Sweden, Reviewed New 
Devices and New Routes for Hypothermia
 He described preclinical and clinical use of hypother-
mia. He also reviewed the different devices used for body 
surface cooling like pads and blankets and intravasal 
whole-body cooling with vena cava catheters of cold flu-
id infusion. A major subset of new devices is designed for 
local cooling, intranasal cooling, head caps, or ice-cold 
pads. The side effects of shivering and pain are still prob-
lematic. At !34°, patients usually have to be fully anes-
thetized. Methods to prevent shivering in awake patients 
include sedation with Meperidine (eg, 0.25 mg/kg/1 hour 
intravenous) with oral Buspirone 20 mg every 8 h.
 Katja Piironen, Helsinki, Finland, Gave an Update
on Hypothermia after Cardiac Arrest and Brain 
Trauma
 Meta-analyses and systematic reviews give no firm 
support for a beneficial effect of hypothermia on mortal-
ity and outcome after trauma. A number of issues in this 
field are still unresolved, including depth and duration of 
hypothermia.
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The situation is better for hypothermia after cardiac 
arrest. According to a Cochrane database meta-analysis 
in 2009, ‘hypothermia seems to improve hospital dis-
charge and neurological outcome after cardiac arrest.’ 
Other systematic reviews come to similar conclusions, al-
though there is still a lack of high-level clinical random-
ized trials. Some randomized controlled trials comparing 
moderate hypothermia (33 ° C) to very mild hypothermia 
(36 ° C) are currently ongoing.
Despite the fact that hypothermia after cardiac arrest 
has received high-level recommendations in recent guide-
lines, there is still plenty of room for improvement. Again, 
as in drug development in which dose-finding is a key is-
sue, deaths from hypothermia, duration of hypothermia, 
and strategy of rewarming in hypothermia are still issues 
that need to be solved.
 Session III: Stem Cell Therapy for Stroke 
 Zaal Kokaia, Lund, Sweden, Discussed Cellular 
Plasticity after Stroke: Important for Recovery?
 Stem cell-based approaches hold much promise as po-
tential novel treatments to restore function after stroke. 
Transplantation of stem cells or their derivatives in ani-
mal models can improve function by replacing the neu-
rons and glia cells lost (as shown in neurodegenerative 
diseases) and through trophic actions, and by modula-
tion of inflammation. Endogenous neural stem cells also 
are potential therapeutic targets because they produce 
neurons and glial cells in response to injury. Clinical tri-
als are ongoing but there are significant hurdles before 
basic research findings can be responsibly translated to 
novel therapies. In particular, there is a need to better-
understand mechanisms of action of stem cells after 
transplantation in stroke-lesioned brain and learn how to 
control proliferation, survival, migration, and differen-
tiation in the pathological environment of grafted and 
endogenously derived stem cells.
 Gianvito Martino, Milan, Italy, Reported on 
Interactions between Stem Cells and the Immune 
System
 Apart from a cell replacement mechanism, neural stem/
precursor cell (NPC) transplantation also may promote 
central nervous system repair via intrinsic neuroprotec-
tive bystander capacities. At the site of tissue damage, un-
differentiated stem cells release neuroprotective molecules 
(eg, immunomodulatory substances, neurotrophic growth 
factors, and stem cell regulators), which are also normally 
expressed by NPC for maintaining tissue homeostasis. 
The ability of transplanted NPC to protect the brain from 
several types of injuries using bystander strategies (‘thera-
peutic plasticity’) is of pivotal importance for the future of 
stem cell-based therapeutic approaches.
 Mathias Hoehn, Cologne, Germany, Presented 
Neuroimaging Aspects on Stem Cell Mediation of 
Functional Recovery after Stroke
 Cell migration from the implantation site may be fol-
lowed with in vivo magnetic resonance imaging (MRI) 
using responsive contrast agents, and cell-specific differ-
entiation processes may be visualized. Functional MRI 
activation studies have demonstrated an unequivocal 
therapeutic improvement after several months indicating 
that regeneration studies in rodents require longitudinal 
investigation protocols. The imaging-based regeneration 
investigations need to be extended beyond the focused 
task-selective brain activation to analyze brain connec-
tivity using resting-state functional MRI. Combining 
resting-state functional MRI with fiber tracking, distur-
bances of structural and functional networks are now in-
vestigated in longitudinal approaches.
 Robert Andres, Bern, Switzerland, Presented 
Further Aspects on Intravascular Stem Cell Therapy 
for Stroke
 Because ischemic stroke commonly affects wide brain 
areas, intravascular delivery of NPC may be a more prom-
ising approach than focal intraparenchymal transplanta-
tion. NPC administered into the carotid artery selective-
ly pass the blood-brain barrier at the infarct site, exhibit 
neural differentiation, and improve functional deficits in 
rodent models. Compared with intravenous injection, in-
tra-arterial administration is a more efficient route, al-
lowing first-pass delivery of the cells to the brain. Critical 
aspects to be addressed include the limited transendothe-
lial homing of NPC, as well as biodistribution and safety 
issues.
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 Keith Muir (Glasgow, United Kingdom) Reported 
that Designs of Human Trials of Stem Cell Therapy 
Will Be Dictated by Preclinical Evidence (Delivery 
Routes/Timings, Cell Properties) and Also by 
Regulatory Perspectives
 Safety trials of cell therapies have used direct intrapa-
renchymal brain injection of allografts or xenografts (3 
completed trials, 2 ongoing) in chronic cases between 6 
months and several years after stroke or intravenous de-
livery of autologous stem cells in the subacute phase. The 
design of Pilot Investigation of Stem Cells in Stroke
(PISCES) trial (ongoing, recruitment target expected 
during 2012), which uses genetically modified human 
neural stem cells delivered by intraparenchymal injec-
tion, was presented.
 Bo Norrving, Lund, Sweden, Presented a
Cost-Effectiveness Study on Stem Cell Therapy
after Stroke
 The study assumptions included direct and indirect 
costs and prognostic data, and modeling was performed 
for age, functional status at discharge, degree of thera-
peutic effectiveness, and 4 other variables. The study 
showed that stem cell therapy offers potential for cost off-
set and cost-savings in the long-term by reducing disabil-
ity after stroke. The treatment appeared cost-effective 
under a wide range of assumptions.
 Session IV: Biomarkers and Stroke 
 Joan Montaner, Barcelona, Spain, Discussed 
Biomarkers in Stroke
 The future value of biomarkers in clinical practice 
might be: (1) to predict stroke risk; (2) to make stroke di-
agnosis; (3) to differentiate stroke subtypes; (4) to estab-
lish outcome; and (5) to use biomarkers as treatment end-
points. In addition, biomarkers may help to understand 
the pathophysiology of stroke, and specific brain bio-
markers might aid in stroke diagnosis and permit rapid 
referral of stroke patients to stroke centers for acute treat-
ments including thrombolysis [9]. To date, diagnostic 
biomarkers such as b-nerve growth factor, interleukin-17, 
tumor necrosis factor receptor-1, and insulin-like growth 
factor-binding protein were shown to differentiate acute 
strokes from stroke mimics. Biomarkers also might yield 
information on evolution and prognosis of stroke that is 
not contained in the clinical data. Such biomarkers in-
clude markers of infarct growth, hemorrhagic transfor-
mation, cardiac complications, infections, or recurrent 
vascular events. They might help to weigh the potential 
risks and benefits of different treatments and to allocate 
resources for stroke treatment. However, whether these 
putative biomarkers will have direct clinical utility is cur-
rently unclear.
 Patrik Michel, Lausanne, Switzerland, Discussed the 
Role of Imaging As a Marker of Viable Tissue
 Although ‘time is brain’ holds true for all acute recan-
alization treatments in ischemic stroke, patient and 
method selection is now shifting toward hyperacute as-
sessment and effective treatment strategies for the oc-
cluded vessel (‘recanalization is brain’) and of viable tis-
sue (‘penumbra is brain’). In clinical practice, the latter is 
best assessed by magnetic resonance perfusion-weighted 
imaging or computed tomography perfusion. Thresholds 
to differentiate nonviable from viable tissue and from be-
nign oligemia now have been better-defined, and auto-
mated threshold maps are available [10]. Randomized tri-
als based on such viable tissue determination (‘mis-
match’) have started (DEFUSE-2, EXTEND) or are 
planned (ECASS-4).
 Hugues Chabriat, Paris, France, Spoke on 
Biomarkers of Small Vessel Disease
 Hugues Chabriat emphasized some of the most recent 
developments on MRI markers of small vessel disease in 
the literature: (1) first report on predictors of incident mi-
crobleeds in the general population; (2) blood products 
within pericytes and erythrophagocytosis as potential 
mechanisms underlying these lesions; (3) accumulating 
evidence of blood-brain barrier alterations in small vessel 
disease using dedicated MRI sequences; (4) increased 
knowledge of the wide spectrum of clinical manifestations 
related to diffuse white-matter changes; (5) further confir-
mation that blood pressure reduction can reduce the pro-
gression of white matter hyperintensities in a population-
based study; (6) dilated perivacular spaces reported as an 
independent MRI marker of small vessel disease related to 
male gender, age, and hypertension with their severity as-
sociated with increased risk of incident dementia; and (7) 
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limitations of MRI diagnostic criteria of so-called silent 
infarcts and recent detection of cortical microinfarct in 
small vessel disease using ultrahigh-resolution MRI.
 Hugh Markus, London, United Kingdom, Discussed 
Genetic Markers of Stroke Risk
 Identifying genetic risk factors for stroke may help in 
both risk prediction in individual patients and in identify-
ing new stroke mechanisms that allow new therapeutic ap-
proaches to be developed. The genome-wide association 
study approach allows 11 million markers spanning the 
genome to be compared between cases and controls. This 
technique does not require any priori hypothesis and, 
therefore, completely novel associations can be detected. 
Genome-wide association study has had a major impact 
on genetics of other complex diseases, with 11,000 new as-
sociations reported by the second quarter of 2010. Initial 
studies in stroke confirmed that genes associated with 
both atrial fibrillation and myocardial infarction also were 
risk factors for stroke. More recently, the Wellcome Trust 
Case Control Consortium 2 (WTCCC2) study has looked 
at 110,000 stroke cases and 50,000 controls and identified 
a novel association at 7p21, which was specific to large ar-
tery stroke [11]. The likely underlying gene is histone 
deacetylase 9. There are a number of potential mecha-
nisms by which altered histone deacetylase 9 activity could 
increase stroke risk. All the genome-wide association 
studies in stroke to date have found associations with spe-
cific stroke subtypes. This emphasizes that the pathophys-
iology of different subtypes differs, and this also may have 
implications for therapeutic responses. It also emphasizes 
that for the maximal chance of success in genetic studies 
in stroke, cases should be carefully phenotyped.
 Christian Foerch, Frankfurt, Germany, Spoke on 
Early Differentiation of Hemorrhage and Ischemia 
by Biomarkers
 The BE FAST study aimed to determine the diagnostic 
accuracy of glial fibrillary acidic protein as a biomarker 
of intracerebral hemorrhage in a prospective and multi-
center setting [12]. Patients suspected of having acute 
hemispheric stroke were included. Glial fibrillary acidic 
protein plasma levels at admission were increased signif-
icantly in patients with intracerebral hemorrhage in com-
parison with patients with ischemic stroke. The chosen 
cut-off level provided a diagnostic sensitivity of 84% and 
a diagnostic specificity of 96% for differentiating intrace-
rebral hemorrhage from ischemic stroke and stroke mim-
ics. Further studies are needed to test a glial fibrillary 
acidic protein point-of-care system that may allow an op-
timized prehospital management of patients with symp-
toms of acute stroke.
 Session V: Anticoagulation and Reperfusion 
 Didier Leys, Lille, France, ‘Ischemic Stroke in
Adults and Genes Interfering with Coagulation, 
Platelet Activation, and Thrombolysis’
 In the keynote lecture, ‘Ischemic Stroke in Adults and 
Genes Interfering With Coagulation, Platelet Activation, 
and Thrombolysis,’ Didier Leys (Lille, France) covered 
the diagnostic work-up of ‘cryptogenic’ ischemic strokes 
in young adults. The work-up often includes tests for 
thrombophilia, although a causal relationship to stroke 
has never been established. Besides, genetic factors influ-
ence efficacy and safety of drugs acting on coagulation, 
platelets, or thrombolysis, but whether they should be 
used in practice remains uncertain. The association be-
tween arterial ischemic stroke and genes interfering with 
coagulation, platelet activity, and thrombolysis was re-
viewed. Most studies on coagulation disorders suffered 
severe methodological limitations, especially small sam-
ple size and publication bias. There is no proof for a caus-
al relationship between any coagulation disorder and the 
risk of ischemic stroke. However, a small effect may exist 
for prothrombin G20210A mutation in adults and pro-
tein C deficiency in children. A single case-control study 
suggests an association between ischemic stroke and 
(high) von Willebrand factor activity, without evidence 
for polymorphisms in genes encoding for platelet recep-
tors or for genes interfering with thrombin formation 
and fibrinolysis (fibrinogen, factor XIIIa activity, throm-
bin-activatable fibrinolysis inhibitor). The influence of 
genetic factors on the efficacy and safety profile of aspi-
rin, clopidogrel, or vitamin K is proven, but the practical 
interest requires trials to evaluate whether a personal-
ized prescription provides a clinical benefit. Genetic 
thrombophilia plays a very small role, if any, in the risk 
of ischemic stroke. Screening is not cost-effective and 
may lead to inappropriate prescriptions. Large, prospec-
tive, population-based studies, as well as trials with per-
sonalized design vs. fixed doses of clopidogrel or warfa-
rin are needed.
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 Atrial Fibrillation and Stroke Prevention Was 
Addressed by Hans-Christoph Diener, Essen, 
Germany
 Oral anticoagulation with vitamin K antagonists 
(warfarin, phenprocoumon) is successful in both prima-
ry and secondary stroke prevention in patients with atri-
al fibrillation, yielding a 60–70% relative reduction in 
stroke risk and 26% relative reduction in mortality com-
pared with placebo. Acetylsalicylic acid reduces the rela-
tive risk of stroke by a nonsignificant 19% compared with 
placebo, and increased bleeding risk offsets any thera-
peutic gain from the combination of acetylsalicylic acid 
with clopidogrel. A number of new drugs for oral antico-
agulation that do not exhibit the limitations of vitamin K 
antagonists have been investigated. These include direct 
factor Xa inhibitors (rivaroxaban, apixaban) and direct 
thrombin inhibitors (dabigatran). Recent studies (RE-LY, 
ROCKET-AF, AVERROES, ARISTOTLE) showed higher 
efficacy and significantly lower incidence of intracranial 
bleeds compared with warfarin. Dabigatran in high dos-
es prevents ischemic strokes in patients with atrial fibril-
lation. Rivaroxaban showed efficacy over warfarin in pa-
tients at high risk with a high CHADS2 score. Apixaban 
showed the lowest rate of major bleeding complications. 
Apixaban also showed clear superiority compared with 
aspirin in patients with atrial fibrillation unsuitable for a 
treatment with warfarin with a comparable bleeding rate. 
The new substances showed similar results in secondary 
as in primary stroke prevention in patients with atrial fi-
brillation.
 Gerhard Schroth, Bern, Switzerland, Reported 
on Advances in Mechanical Recanalization and 
Presented New Devices and Techniques
 Strokes of National Institutes of Health Stroke Scale 
score 612 show large vessel occlusions (carotid T, M1) in 
190%, resulting in low recanalization rates after intrave-
nous thrombolysis. Recent improvements in endovascu-
lar therapy result in recanalization rates up to 90%, cor-
responding with improved clinical outcome [13]. One 
hundred forty-one patients with severe stroke (National 
Institutes of Health Stroke Scale score 18) were treated in 
6 European centers using the Solitaire Retrievable Stent 
System with recanalization rates of 90% and good clini-
cal outcome (modified Rankin Scale score, 0–2) of 55% 
or even 66% in a subgroup treated with intravenous re-
combinant tissue plasminogen activator before mechan-
ical recanalization (bridging therapy). This indicates 
that severe strokes may be candidates for endovascular 
therapy. Prospective randomized trials are urgently 
needed not only to show high rates of recanalization with 
stent retrievers but also to show superiority in clinical 
endpoints.
 Werner Hacke, Heidelberg, Germany, Reported on 
Clinical Endpoint Studies
 At present, up to 25% of all unselected patients with 
acute ischemic stroke may be candidates for device-as-
sisted recanalization therapy. In recent studies, patient 
composition varied largely between reported series. Ca-
rotid T occlusions remain difficult to treat and M1 occlu-
sions are ideal for recanalization with devices. M2 occlu-
sions also might show good results with intravenous 
thrombolysis. Occlusions of the basilar artery need to be 
investigated in separate studies. Until now in prospective 
and retrospective case series, best outcomes were report-
ed with early recanalization. Several series reported late 
onset of treatment, up to 68 h. Individual reports indi-
cate not only delayed start of recanalization but also pro-
cedures 14 or 5 h with several devices used in sequence. 
Time to recanalization may be 110 h.
Recanalization rates with devices range between 42% 
and 90%. To date there is no evidence that clinical out-
come is improved by mechanical recanalization. Regis-
tries and trials with historical controls report low modi-
fied Rankin Scale scores of 0–2 for response rates, high 
mortality rates, and relatively high spontaneous ICH 
rates. This may be an adequate result for the study popu-
lation tested, but without concurrent control this remains 
unknown.
After encouraging data from IMS I and IMS II, IMS 
III is the pivotal trial with 1600 of 900 planned patients 
included. The IMS III has a 2: 1 randomization between 
intervention and systemic thrombolysis, uses many types 
of transvascular therapy including intra-arterial lytics vs 
intravenous recombinant tissue plasminogen activator 
(40 minutes, 0.9 mg/kg), and uses treatment within 6 h 
with the following devices: PENUMBRA, MERCI, SOLI-
TAIRE, and PHENOX.
In the future there will be a number of prospective 
randomized trials comparing recanalization devices 
with intravenous or intra-arterial thrombolytic therapy. 
These trials will show us whether recanalization with de-
vices improves clinical outcome in patients with severe 
strokes.
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 José M. Ferro, Lisbon, Portugal, Discussed Advances 
in Treatment of Cerebral Venous Thrombosis
 Four topics were addressed: type of anticoagulation, 
duration of anticoagulation local thrombolysis, and de-
compressive surgery. In the acute phase, low-molecular-
weight heparin seems to be safer and preferable to intra-
venous heparin. The duration of anticoagulation to pre-
vent recurrent venous thrombotic events after cerebral 
venous thrombosis is uncertain. It will be investigated in 
a randomized clustered trial (EXCOA-CVT), which will 
compare 3 vs. 12 months of anticoagulation. Local intra-
sinus thrombolysis is being investigated in the TO-ACT 
trial, which is randomizing severe cerebral venous throm-
bosis patients between local thrombolysis and anticoagu-
lation. The life-saving role of decompressive surgery in 
cerebral venous thrombosis patients with large herniating 
lesions will be investigated in the DECOMPRESS registry.
 Session VI: Population-Based Interventions 
 Jaakko Tuomilehto, Helsinki, Finland, Gave a 
Keynote Lecture on Population-Based Interventions 
Tested for Community Implementation
 Comparing community approaches to individual ap-
proaches of prevention, Tuomilehto pointed out that in 
community approaches the preventive dose is viable and 
outcomes differ from medical outcomes. Among the pre-
requisites are that it has to be demonstrated that the inter-
vention is working. This can be shown most efficiently us-
ing randomized controlled trials. However, randomized 
controlled trials may not give us the right answer for real 
life or for all people because randomized controlled trials 
always rely on specially selected and small number of peo-
ple. There are 2 potential types of effect modification, re-
ferred to as ‘behavioral effect modification,’ and the im-
pact indicator, referred to as ‘biological effect modifica-
tion.’ Prevention looks at healthy lifestyle vs risk factors 
with the aim to reduce stroke events. One Finnish study 
has shown that a reduction of healthy lifestyle traits to !3 
healthy lifestyle factors increases the hazard ratio for stroke 
from 1.37 (1.02–1.83) to 2.08 (1.56–2.70) in hypertensive 
patients treated with antihypertensive drugs [14]. This il-
lustrates the need to also give attention to lifestyle issues 
even in a situation when evidence-based pharmacotherapy 
is given to the hypertensive patients to prevent stroke.
Nonsmoking regulations, reduction of butter con-
sumption, increase in the use of vegetable oil, and reduc-
tion of salt intake with a target of 5 g/day have massive 
effects on vascular mortality including stroke. Globally, 
the reduction of salt intake by 5 g/day from the present 
level alone would result in a decrease in cardiovascular 
disease mortality by 17% and a decrease in stroke mortal-
ity by 23%. On a global scale this would imply, every year, 
1,265,000 less people with strokes and 3,000,000 less peo-
ple with cardiovascular deaths, overall a reduction of al-
most 5 million deaths per year [15].
Cerebrovascular disease rates, both incidence and case 
fatality, are particularly strongly influenced by socioeco-
nomic factors. Low-income populations show a 2-times 
higher incidence of stroke than high-income populations 
within the same country. Reduction of the burden of 
stroke was recently stressed in the American Guideline 
[16], and a European Guideline also should aim at show-
ing the returns for prevention of stroke.
 Laszlo Csiba, Debrecen, Hungary, Reported the 
Needs and Numbers for Population Interventions
 He reported a focus on Eastern Europe as opposed to 
the countries in Western Europe and showed that the ex-
tent and numbers of risk factors were much higher in 
eastern Europe according to the World Health Organiza-
tion Europe July 2011 data. Comparing these countries, 
there was a 3-fold difference for admission rates of stroke, 
but life expectancy was not so strongly influenced by so-
cioeconomic levels. Similar rates were seen for DALYS, 
showing that the strongest burden of stroke was in males 
between ages 45 and 60 years and in females older than 
70 years.
 Philip Bath, Nottingham, United Kingdom, Talked 
about a Randomized Controlled Trial That Aims to 
Reduce Poststroke Cognitive Decline and Dementia 
by Strict versus Guideline Blood Pressure and/or 
Lipid Lowering
 Philip Bath, Nottingham, United Kingdom, in his lec-
ture on drug compliance and adherence trials, talked 
about a randomized controlled trial (PODCAST,
ISRCTN85562386; http://www.podcast-trial.org/) that 
aims to reduce poststroke cognitive decline and dementia 
by strict vs. guideline blood pressure and/or lipid lower-
ing. He discussed the numbers needed to meet these end-
points and showed some preliminary (blinded) group 
comparisons from his trial.
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 Karl Matz, Krems, Austria, Addressed 
Polyintervention in the Ongoing ASPIS Trial
 Karl Matz, Krems, Austria, addressed polyinterven-
tion (including lifestyle) trials in the ongoing ASPIS
(Austrian Stroke Prevention in Ischemic Stroke) trial
(ISRNCT 01109836), which aims at a reduction of post-
stroke cognitive decline rates in mild stroke patients who 
are cognitively unimpaired at discharge. Patients are ran-
domized to either normal treatment and follow-up or in-
tense follow-up and guidance in establishing and main-
taining a healthy lifestyle.
 Edo Richard, Amsterdam, The Netherlands,
Spoke on Prevention of Dementia by Intensive 
Vascular Care
 Edo Richard, Amsterdam, the Netherlands, speaking 
on prevention of dementia by intensive vascular care, re-
ported the ongoing cluster randomized controlled pre-
DIVA trial that is performed in nondemented communi-
ty-dwelling elderly (n = 3,534) individuals aged 70–78 
years. The intervention consists of multicomponent 
pharmacological and nonpharmacological treatment 
aimed at all vascular risk factors.
 Session VII: Reorganization and Networks after 
Stroke 
Reorganization of surviving brain networks is associ-
ated with functional improvement after stroke and this 
process is likely to be facilitated by neurorehabilitative 
training. Neuroimaging techniques are proving useful in 
the evaluation of novel treatments.
 Rick Dijkhuizen, Utrecht, The Netherlands, 
Described Longitudinal Alterations in Neuronal 
Networks Using Resting-State Functional MRI
 Rick Dijkhuizen, Utrecht, the Netherlands, described 
longitudinal alterations in neuronal networks after an ex-
perimental stroke model in rats using resting-state func-
tional MRI and diffusion tensor imaging. Improvement of 
sensorimotor function was associated with wide-ranging 
changes in functional and structural connectivity within 
bilateral neuronal networks [17]. There was partial nor-
malization of neuronal signal synchronization between the 
affected and unaffected sensorimotor cortices together 
with an increase in network efficiency. These modifica-
tions in cortical network organization were associated with 
an increase of initially declined fractional diffusion anisot-
ropy in perilesional corticospinal tract regions. Correla-
tion analyses revealed that improvement of sensorimotor 
performance scores were associated with restoration of ip-
silesional corticospinal tracts, in combination with rein-
statement of interhemispheric neuronal signal synchroni-
zation and normalization of cortical network organization.
Nick Ward, London, United Kingdom, Discussed 
Brain Activity during Affected Hand Movement 
Nick Ward, London, United Kingdom, described how, 
in humans, increasing damage to the corticospinal sys-
tem leads to a shift of functional MRI-measured brain 
activity during affected hand movement away from pri-
mary motor cortex (M1) toward premotor and supple-
mentary motor areas [18]. In some patients, prominent 
activity also can be seen in the contralesional hemisphere. 
Analysis of connectivity shows that the influence of ip-
silesional on contralesional M1 becomes more facilitato-
ry in these patients. Furthermore, in some cases, the peak 
of corticomuscular coherence (measured using magneto-
encephalography to indicate the cortical region directly 
contributing to motor execution) is seen in contralesion-
al M1. These data support the idea that the brain is able 
to generate descending motor commands from a range of 
cortical motor areas in either hemisphere. Design of ther-
apeutic cortical stimulation studies to enhance the effects 
of training need to take this into consideration.
 Andreas Luft, Zurich, Switzerland,
Discussed the Role of Dopamine and Reward in 
Neurorehabilitation of Stroke
 After stroke, the brain is impaired in processing re-
wards potentially leading to deficits in reward-based 
learning. Destroying dopaminergic projections that most 
likely relay reward signals from the ventral tegmental area 
of the brain stem to primary motor cortex (M1) destroys 
learning in a rat model [19]. Subsequent substitution of 
dopamine into M1 restores learning. Interfering with in-
tracortical dopaminergic signaling inside M1 destroys the 
ability of M1 neurons to undergo long-term potentiation, 
a basic cortical mechanism of motor skill learning. These 
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data indicate that reward processing is integral to motor 
learning and, therefore, motor recovery. Enhancing the 
ability of stroke survivors to assess and process rewards 
has the potential to enhance motor recovery.
 Agnes Floel, Berlin, Germany, Described How
3 Days of Intensive Anomia Training in Chronic 
Aphasia Patients Led to Improvements
 Agnes Floel, Berlin, Germany, described how 3 days of 
intensive anomia training in chronic aphasia patients led 
to improvements in naming ability lasting at least 2 weeks 
after training [20]. Application of anodal transcranial di-
rect current stimulation over the right temporo-parietal 
cortex enhanced the effect of training compared with 
cathodal transcranial direct current stimulation and 
sham stimulations. Subsequently, she applied anodal 
transcranial direct current stimulation over left ventral 
inferior frontal gyrus (a core language area) during func-
tional MRI scanning of semantic word generation. Im-
proved word retrieval during anodal transcranial direct 
current stimulation was paralleled by selectively reduced 
task-related activation in the left ventral inferior frontal 
gyrus and increased connectivity in major hubs of ana-
tomically connected language areas. These results sug-
gest that targeting specific brain regions within spared 
networks in combination with symptom-oriented treat-
ment may help to promote recovery.
 Alex Leff, London, United Kingdom, 
Investigated the Effects of Behavioral Therapy 
Using Functional MRI in Chronic Aphasic 
Stroke Patients
 The speech perception of the patients improved with 
50–100 h of phonological therapy. In the more severely 
affected group, the effects of therapy were correlated with 
changes in brain connectivity between layers of the audi-
tory hierarchy [21]. A feedback connection (from right 
auditory cortex to right thalamus) was significantly 
strengthened, whereas a feedforward connection (from 
right auditory cortex to right planum temporale) was 
weakened. In other words, the feedback connections that 
code predictions have been improved by therapy, leading 
to smaller errors being passed on via the feedforward 
connections. These results illustrate the principle that 
connectivity parameters may be useful biomarkers for 
studying therapy effect.
According to an anonymous survey, the participants 
unanimously appreciated the endeavor of this first Euro-
pean workshop; 90–98% liked the selection of topics and 
speakers, the mixture of basic translational and clinical 
research, the scientific and social interactions, and the 
discussions. Many pointed out the academic noncom-
mercial nature of the event and were enthusiastic to re-
peat the workshop on a regular basis.
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